Floatz logo

Tasisulam

Primary Peritoneal Cancer

Eli Lilly and CompanySmall moleculePhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

154 Active assets in the Primary Peritoneal Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
GOG Foundation
Phase 3BBB
Carboplatin
University of Washington
Phase 3BBB
Inno-206
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
Hycamtin
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
PEGFILGRASTIM
TORL Biotherapeutics, LLC
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Tasisulam is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
metastatic melanomaDormant
CCC
Indicative ·
50 / 100
View asset →
fallopian tube cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →